Diagnostic Testing

3/633 → 11/1156; +0.48 percentage points of formation share.

The clearest pattern in this batch of diagnostic testing startups is that the smartphone has replaced the lab as the site of testing itself, with Tambua Health's NoDraw turning a phone camera into a blood panel, Simple Strips scanning glucose test strips the same way, and Neodocs offering instant nutritional testing through the same device, all racing to eliminate the needle and the courier. Alongside that consumer-facing shift sits a second, disease-specific track aimed at diagnoses that still require real lab science, like AOA Dx's glycolipid biomarker work on ovarian cancer, Digistain's breast cancer diagnostics born out of Imperial College London, and VedaBio's CRISPR-based syndromic testing that promises results in minutes rather than days. A third group is rebuilding distribution rather than the test itself, with Orange Health Labs and Redcliffe Labs scaling on-demand collection across Indian cities and Tuli Health converting all 11,000 independent UK pharmacies into testing points, betting that access, not accuracy, is the binding constraint. This formation's 2.01x growth trails Telemedicine's 2.78x, which makes sense given that virtual care visits generate demand for the at-home or in-pharmacy tests that can close the loop without a clinic visit, while broader Digital Health is actually contracting at 0.41x, suggesting capital is narrowing away from general health software toward things that produce a physical, billable result. The timing tracks the maturing of smartphone camera and sensor capability alongside CRISPR-based diagnostic techniques like SHERLOCK and DETECTR, which only became commercially packageable for point-of-care use in the years following their initial publication, giving founders a real alternative to the traditional wet lab for the first time.

No comparable outside activity is connected yet.